# Navigator Medicines

> Navigator Medicines is a clinical-stage biotech developing antibodies that block two inflammatory signals, OX40L and TNFα, at once. Backed by a $100 million Series A and built around a licensed program from IMBiologics, it is testing NAV-240 in a Phase 2a trial for moderate to severe hidradenitis suppurativa while advancing a longer-lasting follow-on candidate, NAV-242, through Phase 1.

- **Founded:** 2024
- **Headquarters:** San Mateo, United States
- **Founders:** Stephen Thomas (Co-founder; CEO of parent Sera Medicines)
- **Products:** NAV-240, NAV-242, NAV-340
- **Notable:** Closed a $100 million Series A in August 2024., Licensed NAV-240 and an OX40L-focused portfolio from IMBiologics., Completed NAV-240 Phase 1b participant visits in 2025.

## Products & services

- **NAV-240** — Investigational bispecific antibody against OX40L and TNFα; in the Phase 2a MAINSAIL trial for moderate to severe hidradenitis suppurativa.
- **NAV-242** — Investigational half-life-extended, subcutaneous OX40L/TNFα bispecific antibody; first participant dosed in Phase 1 in March 2026.
- **NAV-340** — Early discovery-stage program shown in the company's March 2026 pipeline graphic as targeting OX40L and an undisclosed second target, with atopic dermatitis and asthma listed as potential indications.

## Achievements

- Closed a $100 million Series A in August 2024.
- Licensed NAV-240 and an OX40L-focused portfolio from IMBiologics.
- Completed NAV-240 Phase 1b participant visits in 2025.
- Received US IND clearance for the NAV-240 Phase 2a HS study in January 2026.
- Dosed the first Phase 2a MAINSAIL patient and first Phase 1 NAV-242 participant by March 2026.

## Latest updates

- **2026-03** — First patient dosed in NAV-240 Phase 2a MAINSAIL trial; NAV-242 entered Phase 1; Phase 1b NAV-240 findings presented at AAD.
- **2026-01** — FDA cleared the NAV-240 Phase 2a IND; Australian ethics approval enabled NAV-242 first-in-human study.
- **2025-11** — NAV-240 Phase 1b completed its last participant visit.

## Links

- Website: https://www.navigatormedicines.com/
- LinkedIn: https://www.linkedin.com/company/navigator-medicines-inc

---

Profile page: https://yespress.io/navigator-medicines
Published by YesPress — https://yespress.io
Last updated: 2026-09-30